Improvement in Patient-reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type One Treated With Alixorexton, an Orexin Two Receptor Agonist, in the Vibrance-1 Phase Two Study (P6-14.002)

Y Dauvilliers; R GRUNSTEIN; Emmanuel Mignot; Gerrit Lammers; David Plante; Erik Buntinx; Rafael del Río Villegas; Hailu Chen; Craig Hopkinson; Bhaskar Rege; Julie Himes; Michael Doane; G Plazzi

doi:10.1212/wnl.0000000000216237

June 9, 2026Neurology

Improvement in Patient-reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type One Treated With Alixorexton, an Orexin Two Receptor Agonist, in the Vibrance-1 Phase Two Study (P6-14.002)

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the effects of alixorexton on disease severity, cognitive functioning, and fatigue in patients with narcolepsy type 1.
Randomized trial comparing alixorexton versus placebo
Once-daily oral administration
Assessment of disease severity, cognition, and fatigue
Significant reduction in disease severity scores (exact metrics not provided)
Improvement in cognitive functioning noted
Decrease in fatigue levels assessed through patient-reported measures

Implication

Randomized trial shows reduced disease severity and improved cognition in narcolepsy patients, suggesting effective treatment options.

Abstract

Describe the effect of once-daily alixorexton, an investigational, oral, highly selective orexin 2 receptor agonist, versus placebo on disease severity, cognition, and fatigue in patients with narcolepsy type 1 (NT1).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dauvilliers et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055ed7 https://doi.org/10.1212/wnl.0000000000216237

View Full Paper

Ask AI

Bookmark

Share

Improvement in Patient-reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type One Treated With Alixorexton, an Orexin Two Receptor Agonist, in the Vibrance-1 Phase Two Study (P6-14.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Improvement in Patient-reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type One Treated With Alixorexton, an Orexin Two Receptor Agonist, in the Vibrance-1 Phase Two Study (P6-14.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading